Apixaban Tied to Lower Risk for Recurrent VTE in Dialysis Population
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Rate ratios were highest for critical COVID-19, and during first versus second and third pandemic waves in Sweden
Study is the largest to explore this potential safety issue to date.
There are currently 4 FDA-approved hydroxyethyl starch products on the market.
Intensive BP lowering after intracerebral hemorrhage linked to poorer outcomes in patients with decreased renal function